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A R T I C L E D A T A8 A B S T R A C T
10 Protein array technology has begun to play a significant role in the study of protein–
^
protein
11 interactions and in the identification of antigenic targets of serum autoantibodies in a
12 variety of autoimmune disorders. More recently, this technology has been applied to the
13 identification of autoantibody signatures in cancer.
14 The identification of tumour-associated antigens (TAAs) recognised by the patient's
15 immune response represents an exciting approach to identify novel diagnostic cancer
16 biomarkers and may contribute towards a better understanding of the molecular
17 mechanisms involved. Circulating autoantibodies have not only been used to identify
18 TAAs as diagnostic/prognostic markers and potential therapeutic targets, they also
19 represent excellent biomarkers for the early detection of tumours and potential markers
20 for monitoring the efficacy of treatment. Protein array technology offers the ability to screen
21 the humoral immune response in cancer against thousands of proteins in a high throughput
22 technique, thus readily identifying new panels of TAAs. Such an approach should not only
23 aid in improved diagnostics, but has already contributed to the identification of complex
24 autoantibody signatures that may represent disease subgroups, early diagnostics and
25 facilitated the analysis of vaccine trials.
© 2009 Published by Elsevier B.V.28
29
31 1. Introduction
32 When studying disease processes, the knowledge of altera-
33 tions on protein level, including protein structure, post-
34 translational modifications or protein–
^
protein interactions,
35 is crucial to elucidate complex biological phenomena. Such
36 insights are difficult to attain due to the enormous complexity
37 of the protein world. Traditional methods for the analysis of
38 proteomes include two dimensional gel electrophoresis and
39 mass spectrometry, however; to compliment the functional
40 analysis of proteins on a large scale, proteins can be studied in
41 array formats. Preferably such arrays would contain function-
42 ally active proteins, in all their modified states, immobilised
43 on a surface at high density or in solution in nanowells.
44 Importantly, protein activity is dependant on a wide range of
45factors (post-translational modifications, cellular localisation,
46pH, presence/absence of co-factors, etc.) which makes the
47production of a protein chip containing the whole proteome a
48daunting task.
49Since their introduction over a decade ago [1], protein
50arrays have been successfully used in a wide range of studies.
51Large collections of proteins in an array format enabled
52identification of peptide–
^
protein interactions [2], protein–
53
^
protein interactions [3] and antibody–
^
antigen interactions
54[4]. The specificity of these binding interactions was subse-
55quently confirmed by pull-down, yeast two-hybrid, immuno-
56blot and co-immunoprecipitation experiments. In another
57approach protein arrays were successfully used for identifica-
58tion of novel substrates for arginine N-methyltransferases [5]
59and for protein kinases [6]. More recent studies identified
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60 novel substrates for Ubiquitin-protein ligases (E3s) in yeast [7]
61 and novel substrates for Cyclin-dependent kinase (Cdk5) using
62 commercially available protein microarrays [8,9].
63 In the field of oncology, protein arrays offer huge potential as
64 tools for the identification of cancer biomarkers, in particular
65 auto-antibody/antigen markers. The identification of tumour-
66 associated antigens (TAAs) recognised by the patient's immune
67 system represents an exciting approach to identify novel
68 diagnostic cancer biomarkers and to contribute towards a better
69 understanding of the molecular mechanisms involved. Circu-
70 lating autoantibodies have not only been used to identify TAAs
71 as diagnostic/prognostic markers and potential therapeutic
72 targets [10,11], they also represent excellent biomarkers for the
73 earlydetectionof tumoursandpermitmonitoringof theefficacy
74 of treatment [12,13].
75 Protein array technology has already played a significant
76 role in analyzing autoantibodies in a variety of autoimmune
77 disorders [14–16] and cancers [17,18]. The ability to screen an
78 immune response to a large number of proteins in a high
79 throughput technique cannot
^
only aid in improved diagnosis,
80 but has identified autoantibody signatures that may represent
81 disease subgroups, early diagnostics [19] and facilitate the
82 analysis of vaccine trials [20].
83 This review investigates the current developments in
84 protein array technology and their applications with particu-
85 lar emphasis on the field of tumour-associated antigen (TAA)
86 discovery.
88 2. General applications of protein arrays
89 Protein arrays provide a powerful tool to examine interactions
90 between proteins (including antibodies), peptides, DNA/RNA or
91 chemical compounds on a large scale. In one proof-of-principle
92 experiment, a small number of well-defined protein–
^
protein
93 interactions, including an interaction dependent on a small
94 molecule, were demonstrated in a microarray format [21]. As
95 mentioned above, calmodulin- and phospholipids-interacting
96 proteins have been identified by screening almost 6000 yeast
97 proteins, generated by expressing previously annotated open
98 reading frames [22]. Another approach for the identification of
99 protein–
^
protein interactions on protein arrays is the useof short
100 peptides as bait, which can permit studies of proteins that are
101 otherwise difficult to work with in solution. This approach has
102 been successfully applied to identify cytoplasmic interactors of
103 the platelet integrin αIIbβ3 [2,23]. Protein arrays also make an
104 ideal platform to characterise antibodies. A human protein
105 expression library, involving in situ expression of tens of
106 thousands of recombinant proteins on large membranes, has
107 been successfully screened to identify antibody–
^
protein inter-
108 actions [4], permitting identification of cross-reacting proteins
109 and potential epitope definition.
110 Protein arrays can also be used to determine the target of
111 antibodies previously identified as potentially interesting
112 markers in disease. Our group is presently working to identify
113 the antigens of antibodies, initially identified by immunohis-
114 tochemistry as interesting markers in certain types of cancer.
115 Each antibody can be screened against an appropriate protein
116 expression library. Unlike previous approaches, which could
117 at best identify potential epitopes of a particular antibody, this
118approach identifies the actual target protein. In addition,
119potential cross-reacting proteins can also be identified using
120this method, which is important information for assessing an
121antibody in disease screening procedures. Similarly, protein
122arrays could provide a useful screening technique to be
123introduced into any antibody production process.
124Just as it is possible to characterize the binding of a single
125antibody using protein arrays, it is also possible to character-
126ize many antibodies present in a single sample, such as to
127profile the antibody repertoire in serum or plasma. One
128immediate application is the use of “allergen arrays” to screen
129for the presence of particular IgE molecules in a patient
130sample [24–27]. In a similar fashion, protein arrays can be used
131to profile antibodies present in the blood of patientswith auto-
132immune diseases. Initial auto-antigen arrays consisted of
133almost 200 proteins, peptides and other biomolecules (includ-
134ing several forms of dsDNA and ssDNA) which were known
135auto-antigens to several well characterized auto-immune
136diseases, including rheumatoid arthritis and systemic lupus
137erythematosus [28]. Another approach is to use large arrayed
138libraries of recombinant proteins as a potential auto-antigen
139array. In a proof-of-principle experiment, a protein array chip
140containing almost 2500 purified recombinant human proteins
141was used to profile the auto-antibodies present in small
142volume samples from patients with alopecia and rheumatoid
143arthritis [29]. This approach permitted the identification of
144previously known auto-antigens and also previously unchar-
145acterized protein auto-antigens. Initial results from screening
146a large recombinant mouse protein array also indicate the
147usefulness of this approach to characterize auto-immune
148disease in a mouse model system for systemic lupus
149erythematosus [14].
1513. Autoantibody responses in cancer
152Antibody responses to tumour associated antigens in cancer
153patients have been identified in many cancer types and offer
154new biomarkers with potentially high levels of specificity and
155sensitivity (see Table 1). The processes by which such self-
156proteins become immunogenic are not entirely understood
157[30]. However, the molecular changes in structure or expres-
158sion of proteins during tumorigenesis suggest mechanisms by
159which such proteins could be perceived by the immune
160system as foreign and initiate antibody production.
161The most extensively researched mechanisms of cancer
162immunity are genetic mutations leading to expression of
163defective tumour suppressor p53. These frequentmutations in
164many cancer types, lead to conformational changes in the
165protein. This in turn results in increased stability of the
166protein and extended half life time of several hours compared
167with 20 min for wild-type p53 [31,32]. It is generally accepted
168that p53mutations are not directly responsible for priming the
169antibody production, but rather that it is caused by the high
170antigenic load resulting from the accumulation of the p53
171protein [33]. The disparity between the mutation site and the
172actual epitopewas also observed for Ras p21 in cancer patients
173[34]. Interestingly, in both cases the accumulation of the
174protein is required for the antibody response, however, the
175accumulation of the protein does not always result in antibody
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176 production. Of all cancer patients with p53 mutations,
177 approximately half have detectable serum antibodies specific
178 to the p53 protein.
179 A recent study by Engelhorn and colleagues investigated
180 the direct potential of mutations to induce antibody-mediated
181 immune responses [35]. The group found inmice experiments,
182 using combinatorial DNA libraries encoding large numbers of
183 randommutations in tyrosinase-related proteins, that trunca-
184 tions of the tyrosinase protein are sufficient to elicit antibody
185 production. Additional amino acid substitutions in the protein
186 can further enhance these immune responses. Antibody
187 responses to mutated gene products were also identified at
188 advanced stages of cancer, including in a mouse model [36].
189 Since thousands of genes can mutate during the progression of
190 cancer [37], these findings demonstrated the potential of stage-
191 specific immune responses.
192 An alternative pathway leading to initiation of antibody
193 production is the deregulation of gene expression. The
194 expression of many genes in cancer is deregulated and
195 many genes are overexpressed [38]. For example, the non-
196 secreted surface antigen GA733-2 is over-expressed in over
197 90% of colorectal cancers and anti-GA733-2 antibodies were
198 detected in 14.5% of the patients [39]. A further example is the
199 HER-2/neu protein, which is overexpressed in approximately
200 20% of colorectal cancer patients. HER-2/neu antibodies were
201 detected in 46% patients overexpressing the protein and in
202 only 5% patients with no detectable HER-2/neu [40]. The
203 overexpression of genes may lead to an increased antigenic
204 loadwhich in return can be sensed by the immune systemand
205 lead to antibody production.
206 Aberrant cellular localization of antigens caused by malig-
207 nant transformation of mammalian cells might represent a
208 further potential pathway triggering autoantibody responses
209 in cancer patients. The cAMP-dependent protein kinase A
210 (PKA) is an intracellular enzyme [41,42] which can be secreted
211 by cancer cells into the conditioned medium [43,44]. This PKA,
212 designated as extracellular protein kinase A (ECPKA), is often
213 found to be up-regulated in the serum of cancer patients
214 [43,44] which correlates with the presence of ECPKA specific
215 autoantibodies in sera of corresponding patients [45].
216 A further potential mechanism by which self-proteins could
217 trigger antibody production is expression of genes that are not
218 usually expressed in a particular tissue. The mRNA binding
219protein p62 is normally expressed in the foetus and its
220expression is silenced in adult tissue. In some cases of hepato-
221cellular carcinoma, p62 expression can be reinstated leading to
222recognitionby the immunesystemandantibodyproduction [46].
223Another example is a group of proteins normally expressed in
224testicular tissue and not recognised by the immune system as
225foreign (e.g.: NY-ESO-1, SSX2). When, however, aberrantly
226expressed in tumour cells, these proteins can trigger antibody
227responses [47].
2294. Cancer autoantibody discovery in the
230proteomic age
231The vast amount of potential molecular changes during
232tumorigenesis in different cancer types and the individual
233variances in immune responses in cancer patients potentially
234result in complex antibody repertoires. In order to identify a
235disease specific antibody profile it is required to analyse as
236many potential antigens as possible.
237Classical laboratory methods, such as Western blotting or
238enzyme-linked immunosorbent assays (ELISA), have been
239used to identify a number of tumour antigens. Antibodies to
240p53, p21 ras or Her/2neu were successfully identified in cancer
241patients in the previous two decades [34,48,49]. Several novel
242approaches have been developed to detect new antigens that
243elicit antibody responses. With the advent of proteomics and
244recombinant technologies, it is now possible to characterise
245hundreds of proteins in parallel for potential antibodies in sera
246of cancer patients. Followed by a short description of methods
247based on 2D gel electrophoresis, mass spectrometry and
248phage display we will focus our review on protein arrays as a
249tool for detection of antibodies associated with cancer.
250Proteomics is an alternative approach for identification of
251novel tumour antigens. Proteomics applies two dimensional
252gel electrophoresis (2DE), a process that separates large
253mixtures of proteins from natural sources such as tissue or
254cell lines. Once the proteins are separated using 2DE and
255transferred onto protein binding membranes using Western
256blotting, the autoantibodies can be identified by incubation
257with serum of cancer patients [50,51]. Although the natural
258protein source allows analysis of proteins in post-translation-
259ally modified states. a disadvantage of 2DE is that very large or
Table 1t1:1 – Examples of both protein (non-antibody) and autoantibody cancer markers
t1:2
t1:3
Protein (non-antibody) biomarker Swiss-prot ID
^
Cancer type Specificity Sensitivity Reference
t1:4
^
Prostate-specific antigen PSA
^
Prostate cancer 92%⁎ 12%⁎ [87]
t1:5
^
Carcinoembryonic antigen CEA
^
Colorectal cancer 90% ⁎⁎ 34% ⁎⁎ [88]
t1:6
^
Cancer antigen CA15-3 CA15-3
^
Breast cancer 69% 23% [89]
t1:7
^
Cancer antigen CA19-9 CA19-9
^
Gastrointestinal cancer 86% 35% [90]
t1:8
^
Cancer antigen CA125 CA125
^
Ovarian cancer 41.5%⁎⁎⁎ 80%⁎⁎⁎ [91]
t1:9
t1:10 Autoantibody biomarker Swiss-prot ID
^
Cancer type Specificity Sensitivity Reference
t1:11 cAMP-dependent protein kinase A ECPKA
^
Several caner types 90% 87% [45]
t1:12
^
Annexin XI-A ANXA11
^
Breast cancer 88% 77% [92]
t1:13
^
Tumour suppressor p53 p53
^
Several caner types 96% 30% [93]
t1:14
^
Huntingtin interacting protein 1 HIP-1
^
Prostate cancer 73% 46% [94]
⁎3.1–
^
4.0 ng/ml PSA level ⁎⁎5 ng ml−
^
1 CEA level ⁎⁎⁎330 U/mL CA125.t1:15
Autoantibody based biomarkers show promising results and are currently a focus of cancer diagnostic research.t1:16
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260 very small proteins and certain kinds of proteins such as
261 membrane proteins, are difficult or impossible to visualize
262 using 2DE and require further characterisation using mass
263 spectrometry [52].
264 An alternative proteomics approach combines liquid phase
265 protein separations with microarray technology. Proteins in
266 cell and tissue lysates can be separated using chromatography
267 and hundreds of lysate fractions can be arrayed onto
268 nitrocellulose-coated slides [53]. Incubation of serum samples
269 with lysate arrays may reveal fractions immunoreactive with
270 serum antibodies. A study by Nam and colleagues used a
271 fractionated colon adenocarcinoma cell line and identified
272 ubiquitin C-terminal hydrolase isozyme 3 as an antigen
273 eliciting antibody responses in a group of colon cancer
274 patients [54]. The merit of post-translationally modified
275 antigen detection is reduced by difficulties in characterising
276 the identity of antigens, since each fractionmay still contain a
277 complex mixture of proteins.
278 These proteomics approaches represent a large step
279 towards the identification of novel antigens eliciting antibody
280 responses in cancer patients. However, identification of
281 immune responses to a broad set of antigens in cancer is
282 limited to individual and often abundant proteins. Without
283 doubt, the technical advances in separation methods, image
284 analysis and mass spectrometry will retain proteomics as a
285 vital tool for antibody identification.
286 In recent years various protein array techniques combined
287 with more classical research methods have been successfully
288 applied to identify cancer associated autoantibody markers.
289 Novel autoantibodieswere identified in sera of hepatocellular-
290 carcinoma patients using 2DE proteomic method. The validity
291 of these findings was confirmed using a protein array
292 consisting of the corresponding antigens [55]. Generation of
293 protein arrays based on protein sources frommalignant tissue
294 samples is another potentially important step due to advances
295 in protein fractionation methods and mass spectrometry
296 supported by supervised learning analysis of gathered data.
297 Two recent studies focusing on lung and prostate cancer
298 utilized 2D gel electrophoresis and liquid phase chromato-
299 graphy methods respectively as means for generation of
300 highly specialised protein arrays for autoantibody discovery
301 [56,57]. A growing number of current studies strongly indicate
302 that protein arrays are emerging as a tool of choice for
303 research towards deciphering complex protein–
^
protein inter-
304 actions, in particular for the discovery of novel autoantibody/
305 autoantigen biomarkers. Suchwork has enormous potential in
306 the discovery and development of panels of such biomarkers,
307 which appear to offer superior accuracy in disease diagnosis
308 compared to individual markers [58].
309 Phage display offers a powerful platform for identification of
310 tumour associated antibodies [59]. Serological analysis of phage
311 libraries was first introduced in 1995 by Sahin and colleges [60].
312 Phage display technology allows presentation of peptides and
313 proteins derived from human cDNA libraries on the surface of
314 bacteriophage and testing these for reactivity with serum
315 antibodies. Individual immuno-reactive clones can be enriched
316 in a multi-step biopanning procedure from the random phage
317 libraries and characterized by sequencing. A great advantage of
318 phage display is the very large number of potential antigens
319 encoded by the cDNA libraries. This enables detection of a wide
320range of cancer-specific antibodies/antigens [61]. However,
321phage display technology is labour-intensive and peptides
322expressed by phages are often generated from untranslated
323DNA sequences and do not correspond to native antigens, thus
324limiting identification of molecular targets in cancer [11,62].
325Recent technical advancesenable generationof phage-based
326protein/peptide arrays containing several hundred up to several
327thousand phages [11]. Screening the initial phage library with
328pooled sera from several patients and pooled sera from non-
329cancer controls identified in amulti-step biopanning procedure
330approximately 2
^
000 immunoreactive clones. These clones were
331then arrayed on glass-slides and re-screened for immuno-
332reactive clones with non-pooled serum samples. The phage
333array technology allowed the identification of two panels of
334antigens specific for prostate and lung cancer [11,63]. Both
335panelswere able to predict cancerwith over 80% sensitivity and
336specificity.
337The success rates of phage based screening methods were
338critically improved with the introduction of protein arrays
339consisting of antigens identified in concluding steps of phage
340selection [11]. These recent developments permit screening to
341focus on several hundred to a few thousand i
^
dentified leads
342and validate these in larger cohorts of patients using protein
343arrays [63].
3455. Generation of protein arrays for profiling
346autoantibody repertoires in cancer
347The first requirement towards the generation of protein arrays
348is a source of large numbers of recombinant proteins. A number
349of strategies are currently employed to provide sources of
350thousands of proteins for the generation of protein arrays. One
351approach ishigh-throughput cloning or amplification using PCR
352of defined open reading frames coding for the proteins of
353interest [64,65]. The successful implementation of such an
354approach relies on the availability of sequence data and its
355correct annotation in the databases. In particular, the definition
356of the open reading frames of alternative splice variants of one
357protein remains difficult with such an approach. Also, pre-
358viously uncharacterised proteins will be absent, limiting this
359approach as a discovery tool. For these reasons, this approach
360has provedmost valuable in the production of chips containing
361proteins fromwell characterized organisms, such asArabidopsis
362[64] and Caenorhabditis elegans [66].
363Another approach is the use of protein expression libraries,
364which are used for a “shotgun” approach to generate
365recombinant proteins [1]. Such libraries are generated using
366mRNA isolated directly from the cell [67,68]. Here, mRNA is
367isolated from the tissue or organism of interest and direction-
368ally sub-cloned into a protein expression vector, suitable for
369heterologous expression in either a bacterial (e.g. E. coli) or
370eukaryotic organism (e.g. yeast). Several solutions exist for the
371rapid movement of coding region from one organism to
372another, such as the GATEWAY system (Life Technologies)
373[69] or dual expression vectors [67]. Not only does this
374approach circumvent the cloning of individual open reading
375frames, readily permitting the expression of tens of thousands
376of proteins, but also this strategy automatically includes splice
377variants and previously uncharacterized gene products
^
.
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378 The Gateway technology has been successfully applied for
379 cloning the Ultimate™ ORF Clone collection resulting in
380 generation of human protein expression clones for protein
381 array applications. Recombinant bacmid DNA were isolated
382 and transfected into Sf9 insect cells in order to generate a
383 recombinant baculovirus that was used for expression experi-
384 ments. A major advantage of this approach is the generation
385 of protein arrays containing native proteins which are post-
386 translationally modified [18].
387 Apart from just the question of expressing the recombinant
388 proteins of choice in a particular host system, there is also the
389 question of tagging these proteins. A large number of tags
390 exist, the coding region of which can readily be introduced
391 into vectors. Depending on the approach taken, many options
392 are available, including N-terminal and/or C-terminal tagging,
393 multiple different tags are also an option, in particular in
394 conjunction with proteolytic sites for subsequent removal of
395 the tag, if required. These tags can vary in size from the short
396 His6 tag to the 30 kDa GFP tag. Such tags are required for the
397 detection of the expressed recombinant proteins and, in
398 conjunction with an appropriate affinity separation method,
399 for their purification. For a review of different expression
400 systems see [70].
401 In one example, a human foetal brain cDNA library was
402 subcloned into a bacterial expression vector, permitting
403 controlled IPTG-inducible expression of His6-tagged recombi-
404 nant proteins [1]. The E. coli clones of this library were then
405 arrayed in high density onto PVDF membranes, grown over-
406 night and recombinant protein expression induced for a
407 controlled length of time. Those clones expressing a human
408 protein are readily detected bymeans of an anti-His6 antibody.
409 In this fashion, a protein array containing 10–
^
12,000 different
410 human proteins has been generated. Approximately 66% of
411 the proteins expressed in this library are, according to present
412 annotation, full length. Also, such proteins have been shown
413 to be readily expressed and purified in high-throughput using
414 available automated platforms [29,71].
415 In the recent years several novel methods have been
416 developed for cell free in situ synthesis of protein arrays [72–75].
417 In situ protein array synthesis uses cell free expression systems
418 to produce proteins directly from nucleic acid templates. The
419 major advantage of these methods is the expression of many
420 proteins inparallel onachip,avoiding labour intensiveandoften
421 costly processes of DNA cloning, expression and protein
422 purification. The in situ cell free protein generation methods
423 show the capability of high-yieldandhigh-throughput synthesis
424 of hundreds of proteins with minimal variation and good
425 reproducibility [76]. In addition, these methods demonstrate
426 intrinsic purity of synthetized proteins [74] whichmakes thema
427 desirable tool for TAA detection from complex and polyclonal
428 antibody mixtures present in blood of patients. The high purity
429 of proteins arrayed on such self-assembling chips encourages
430 applications in cancer immunology, as outlined in a recent
431 breast cancer study. The findings show that the identified
432 autoantibody profiles are less prone to false positive results due
433 to highly pure proteins directly assembled on the chip [77]. An
434 extensive review on cell free protein array synthesis methods
435 was recently published by He et al [78].
436 Once a source of proteins has been established, considera-
437 tionmust be given to the format that a proteinmicroarray can
438have. Presently, there is a number of possible surfaces
439available for the manufacture of protein arrays. In general,
440chip surfaces can be divided into two major categories: flat
441(planar), and 3D (mostly gel-like) surfaces [79,80]. Planar
442surfaces have been primarily developed in the area of cDNA
443arrays. The glass surface of these chips is usually treated to
444produce a thin layer of a particular chemical group, e.g. an
445aldehyde group or poly-
^
L-Lysine [81]. The proteins are bound
446to the surface of these chips by either covalent bonds or simple
447electrical charge. Another type of planar chip surface available
448is plastic polymer coated slides, such as the MaxiSorb slides
449from Nunc
^
— an approach used in ELISAs for many years. The
450simple adoption of technology from the area of cDNA arrays
451brings with it a number of major concerns when used with
452proteins. Firstly, unlike DNA, the surface charge of proteins is
453highly variable and the use of simple uniform electrostatic
454interaction for the immobilisation of different proteins results
455in large variation in the amount of protein bound. Secondly,
456the structural conformation of proteins deposited onto a
457planar surface cannot be expected to very closely mimic
458“native” proteins, but would be more similar to proteins
459present on membranes, such as in traditional Western
460blotting or dot blot experiments. Thirdly, there is no control
461over the orientation of the proteins on the surface, whichmay
462result in, for example, the inaccessibility of an active site.
463The development of the gel-like 3D chip surface was partly
464driven in an attempt to minimise the denaturation of the
465immobilised proteins in the arrays. A number of such surfaces
466exist based around polyacrylamide and agarose coated on a
467glass surface, which provide a hydrophilic environment for
468the proteins. Such surfaces allow the user to adjust various
469conditions, such as pH and salt concentrations, by incubating
470the chips in the appropriate buffer. Using a “home made”
471polyacrylamide surface, a glass chip containing 2413 non-
472redundant purified human fusion proteins, arrayed at a
473density of up to 1600 proteins/cm2, has been successfully
474employed in antibody binding studies, including the screening
475of human serum samples [29], indicating themaintenance of a
476degree of structural conformation of the proteins involved.
477There are also non-gel-like 3D surfaces available, such as the
478FAST slides from Schleicher and Schuell which have a
479nitrocellulose surface. Like any 3D surface, these surfaces
480allow a much higher concentration of proteins per spot.
481However, these surface solutions still leave the problem of
482controlling the orientation of the proteins on the surface of the
483slides, which is necessary to maximise the activity of these
484proteins. For example, in order to maximise the binding of
485antibodies arranged on a surface to their epitopes, it would
486clearly be an advantage if the heavy chain were attached to, or
487close to, the surface and the antigen binding site as far away
488from the surface as possible. One approach has been the use of
489affinity tags, for example a nickel-coated slide has a natural and
490specific affinity to His6-tagged recombinant proteins. This
491approach was used to array 5
^
800 yeast proteins which were
492screened for their ability to interact with calmodulins and
493phospholipids [22]. Similarly, successful orientation of antibo-
494dies and antibody Fab fragments was achieved by biotinylating
495such antibodies/Fab fragments and arraying them on a strepta-
496vidin-coated surface [82]. A further development of surface
497chemistry involves the use of a polyethylene glycol layer (PEG)
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498 [80] or dendrimers [83]. These approaches involve the coupling
499 of the proteins to epoxy groups, which act as spacers preventing
500 direct protein-surface contact and, thus, eliminate the need for
501 blocking reagents to reduce background binding. One further
502 development of this approach has been to link chelating
503 iminodiacetic acid groups to PEG, which in turn can be bound
504 byCu2+ ionsandsoprovideahighly specific binding site forHis6-
505 tagged proteins [72]. A number of studies have been carried out
506 comparing the different surfaces available for protein array
507 work, includingantibodyarrayswhichassessbackgroundnoise,
508 sensitivity/detection limits, reproducibility and storage for a
509 variety of experimental designs [79,80].
510 While the development of 3D surfaces and spacers partially
511 addresses the problems of protein–
^
protein interactions on a
512 chip, many experiments that involve interactions of proteins in
513 a functional state will prove difficult to perform on these chips,
514 which is obviously a major drawback of the current protein
515 arrays. Ideally, we would like to look at protein interactions,
516 where the proteins are in their native state and are functional,
517 i.e. in conditionsascloseaspossible to those innature.Thismay
518 be solved by developing a microfluidic chip, which is a series of
519 enclosed micro-channels within a chip format, such as silicon,
520 plastic or glass. The potential of microfluidic chips would
521 include the ability to maintain proteins in their functional
522 conformations and to therefore perform interactions such as
523 protein–
^
protein, protein–
^
peptide, protein–
^
compound, protein–
524
^
DNA, protein–
^
ligand and protein–
^
antibody interactions in
525 solution. Also, the area of enzyme studies would greatly profit
526 fromsucha system. In fact the first stepshavebeen taken touse
527 a “lab-on-a-chip” to study someof the reactions in the glycolytic
528 pathway of yeast. Using this system, enzymatic reactions in
529 volumes as low as 6.3–
^
8 nL could be studied [84]. The ability to
530 use such small volumes in microfluidic chips is very important
531 due to the high cost of proteins, antibodies, compound libraries,
532 peptides and even the difficulties in obtaining enough patient
533 samples to screen inhigh-throughput. Another exciting innova-
534 tion is the first attempts to establish a lipid bilayer membrane
535 chip that would allow the functional investigation of trans-
536 membrane proteins and their interactors [85]. These advances
537 would also permit a more thorough exploitation of the libraries
538 of proteins that currently exist.
539 The antibody repertoires in humans consist of a complex
540 polyclonal mixture of antibodies with a wide range of
541 specificities, resulting in immunoreactivity with a vast
542 number of potential antigens. Consequently, minute impu-
543 rities of a protein sample on a protein array may result in a
544 non-specific false-positive signal. To assure the analytical
545 quality of protein microarray experiments, the protein array
546 production and antibody profiling experiments require high-
547 est standard and quality. Appropriate quality control and
548 assurance measures are extensively described in an review
549 article by Kricka and Master [86].
551 6. Conclusion
552 The understanding of molecular events leading to cancer is of
553 the utmost importance to identify effective diagnostic and
554 therapeutic targets.With the complexity of cells and organisms
555 a genome-wide gene expression and protein analyses are
556essential to elucidate human diseases in terms of dysfunctions
557of molecular systems. This is especially true for cancer, where
558multiple key molecular alterations may destabilize essential
559molecular pathways setting off an avalanche of associated
560modification on molecular and cellular levels leading to
561malignancy. As outlined in this review the humoral immune
562responses to tumour antigens offer an exciting opportunity to
563identify autoantibody based diagnostic biomarkers. The
564immune systemmay serve as a sensitive tool to detect minute
565amount of cancer specific antigens amplifying autoantibody
566responses to a measurable level. However, in addition to the
567complexity of cancer, the vast quantity of antibodies circulating
568in human blood and the diversity between individuals needs to
569be taken into account. In this context, individual patients
570produce an immense repertoire of antibodies of which many
571might be not cancer related. Therefore, to comprehensively
572study autoantibodies in patients and to identify cancer specific
573autoantibody signatures the research relies on large sets of
574proteins which can serve as potential antigens. The recent
575developments in protein array technology deliver an excellent
576tool for analysis of thousand of proteins for their antigenic
577ability. Supportedbycurrent findings, amajor futureapplication
578of high-content protein arrays will contribute to the identifica-
579tion of novel of tumour associated autoantibodies as diagnostic
580markers for cancer.
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